Jefferies lowered the firm’s price target on Hims & Hers to $24.50 from $25.50 and keeps a Hold rating on the shares after the company missed on Q1 revenue and EBITDA estimates while cutting FY26 EBITDA guidance by $25M at both ends of the range. The firm views Hims as “an execution story now,” but adds that “investors want to ensure that the (company’s) earnings power has bottomed before driving the stock much higher.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Morning News Wrap-Up, 5/12/26: Today’s Biggest Stock Market Stories!
- Hims & Hers Health Stock (HIMS) Sinks on Dismal Q1 Earnings and Outlook; Here’s What Analysts Are Saying
- Morning Movers: Zebra surges and Under Armour plummets after Q1 results
- Video: GameStop slips after eBay turns down takeover offer
- Hims & Hers Health: Hold Maintained as Profitability Pressures Offset Growth; $21 Price Target Reiterated